Cargando…
The impact of HLA class I and EBV latency‐II antigen‐specific CD8(+) T cells on the pathogenesis of EBV(+) Hodgkin lymphoma
In 40% of cases of classical Hodgkin lymphoma (cHL), Epstein–Barr virus (EBV) latency‐II antigens [EBV nuclear antigen 1 (EBNA1)/latent membrane protein (LMP)1/LMP2A] are present (EBV(+)cHL) in the malignant cells and antigen presentation is intact. Previous studies have shown consistently that HLA‐...
Autores principales: | Jones, K., Wockner, L., Brennan, R. M., Keane, C., Chattopadhyay, P. K., Roederer, M., Price, D. A., Cole, D. K., Hassan, B., Beck, K., Gottlieb, D., Ritchie, D. S., Seymour, J. F., Vari, F., Crooks, P., Burrows, S. R., Gandhi, M. K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4711160/ https://www.ncbi.nlm.nih.gov/pubmed/26422112 http://dx.doi.org/10.1111/cei.12716 |
Ejemplares similares
-
EBV in Hodgkin Lymphoma
por: Massini, Giuseppina, et al.
Publicado: (2009) -
HLA Associations in Classical Hodgkin Lymphoma: EBV Status Matters
por: Huang, Xin, et al.
Publicado: (2012) -
A case of nodular lymphocyte predominant Hodgkin lymphoma with unexpected EBV-latency type
por: Rosenfeldt, Mathias T., et al.
Publicado: (2020) -
Risk factors for Hodgkin's disease by Epstein-Barr virus (EBV) status: prior infection by EBV and other agents
por: Alexander, F E, et al.
Publicado: (2000) -
The switch between EBV latency and replication.
por: Miller, G.
Publicado: (1989)